These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27357629)

  • 1. Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.
    Crooke ST; Baker BF; Kwoh TJ; Cheng W; Schulz DJ; Xia S; Salgado N; Bui HH; Hart CE; Burel SA; Younis HS; Geary RS; Henry SP; Bhanot S
    Mol Ther; 2016 Oct; 24(10):1771-1782. PubMed ID: 27357629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.
    Crooke ST; Baker BF; Witztum JL; Kwoh TJ; Pham NC; Salgado N; McEvoy BW; Cheng W; Hughes SG; Bhanot S; Geary RS
    Nucleic Acid Ther; 2017 Jun; 27(3):121-129. PubMed ID: 28145801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
    Rabinovich-Guilatt L; Elgart A; Erisson L; Willsie SK; Tessler S; Barnett-Griness O; Pande A; Spiegelstein O
    Br J Clin Pharmacol; 2015 Sep; 80(3):436-45. PubMed ID: 25782535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.
    Henry SP; Narayanan P; Shen L; Bhanot S; Younis HS; Burel SA
    Nucleic Acid Ther; 2017 Aug; 27(4):197-208. PubMed ID: 28541820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
    Kim TW; Kim KS; Seo JW; Park SY; Henry SP
    J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
    Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
    J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity Assessment of Inotersen, a 2'-
    Yu RZ; Wang Y; Norris DA; Kim TW; Narayanan P; Geary RS; Monia BP; Henry SP
    Nucleic Acid Ther; 2020 Oct; 30(5):265-275. PubMed ID: 32833564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.
    Kang H; Fisher MH; Xu D; Miyamoto YJ; Marchand A; Van Aerschot A; Herdewijn P; Juliano RL
    Nucleic Acids Res; 2004; 32(14):4411-9. PubMed ID: 15316104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical modification study of antisense gapmers.
    Stanton R; Sciabola S; Salatto C; Weng Y; Moshinsky D; Little J; Walters E; Kreeger J; DiMattia D; Chen T; Clark T; Liu M; Qian J; Roy M; Dullea R
    Nucleic Acid Ther; 2012 Oct; 22(5):344-59. PubMed ID: 22852836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement C3d/C4d Deposition on Platelets Correlates with 2'-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys.
    Shen L; Wong A; Oneda S; Curtis BR; Schroeder J; Zanardi T; Engelhardt JA; Henry SP; Narayanan P
    Nucleic Acid Ther; 2023 Jun; 33(3):209-225. PubMed ID: 37093125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical and transdermal delivery of antisense oligonucleotides.
    Brand RM
    Curr Opin Mol Ther; 2001 Jun; 3(3):244-8. PubMed ID: 11497348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side-effects and phosphorothioates.
    Eckstein F
    Nat Biotechnol; 2002 Jun; 20(6):549. PubMed ID: 12042851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.